ClinicalTrials.gg
RecruitingNCT07276958Updated Oct 8, 2026

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

A Phase 1 interventional study of LY4298445 and LY4298445 in Healthy, Systemic Lupus Erythematosus and Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 8, 2026First site in Japan1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Eli Lilly and Company.

Planned enrollment
10th of 11
68 · median 778
Started
2026
the only one that year
Phase 1
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 1, and was the 11th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

1 of the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company is open now, in 3 countries.

By country, each count listing its studies:

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks.

03

Conditions studied

  • Healthy
  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Healthy Participants

Healthy participants between the ages of 18 and 55 years.

  • Have body weight of at least 50 kilograms (kg) and (BMI) between 18 and 32 kilogram per square meter (kg/m²), inclusive.

Participants with Systemic Lupus Erythematosus (SLE)

  • Are 18 to 75 years of age, inclusive.
  • Have body weight between 45 and 145 kg, inclusive, and BMI between 18 and 35 kg/m², inclusive.
  • Have a clinical diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria at least 6 months prior to screening.

Participants with Rheumatoid Arthritis (RA)

  • Are 18 to 75 years of age, inclusive.
  • Have body weight between 45 and 145 kg, inclusive, and BMI between 18 and 35 kg/m², inclusive.
  • Have a diagnosis of adult-onset RA for at least 6 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria
  • Have Disease Activity Score in 28 joints (DAS28)-high-sensitivity C-reactive protein (hsCRP) greater than or equal to 3.2.
  • Have positive test results for rheumatoid factor or anti-citrullinated peptide antibodies
  • Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 2 advanced therapies (biological disease-modifying antirheumatic drug [bDMARD] or targeted synthetic DMARD [tsDMARD]) after failing a conventional synthetic DMARD (csDMARD).

Exclusion Criteria:

  • Have known allergies to LY4298445, related compounds, or any components of the formulation
  • Are individuals assigned female at birth (AFAB) who are lactating or have a positive pregnancy test at screening or Day -1.
  • Have severe active lupus-associated renal disease (lupus nephritis) defined clinically and/or by

    • urine protein/creatinine ratio greater than 200 milligrams per millimole (mg/mmol) (as an estimate of approximate proteinuria greater than 2 reams (g) per day) or
    • an estimated (eGFR) less than 40 milliliters per minute (mL/min)/1.73 m² at screening, as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) 2021.
    • requiring hemodialysis within 6 months prior to screening
  • Have active central nervous system lupus as defined by ACR nomenclature for neuropsychiatric lupus syndromes and as captured by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, and cerebrovascular accident, within 2 months prior to screening
  • Have a Class 4 RA according to the ACR revised criteria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    LY4298445 (Part A1)

    Single-ascending dose (SAD) of LY4298445 administered subcutaneously (SC) or intravenously (IV) in healthy participants

    Drug: LY4298445

  • Placebo comparator
    LY4298445 Placebo (Part A1)

    SAD of LY4298445 administered SC or IV in healthy participants

    Drug: LY4298445

  • Experimental
    LY4298445 (Part A2)

    SAD of LY4298445 administered SC in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)

    Drug: LY4298445

  • Experimental
    LY4298445 (Part B)

    Multiple-ascending doses (MAD) of LY4298445 administered SC in participants with SLE or RA

    Drug: LY4298445

  • Experimental
    LY4298445 (Part C)

    Single dose of LY4298445 administered SC in healthy Japanese and, optionally, Chinese participants

    Drug: LY4298445

  • Placebo comparator
    LY4298445 Placebo (Part C)

    Single dose of LY4298445 administered SC in healthy Japanese and, optionally, Chinese participants

    Drug: LY4298445

Interventions

  • DrugLY4298445

    Administered SC

  • DrugLY4298445

    Administered IV

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY4298445

    PK: AUC of LY4298445

    Time frame: Baseline up to Approximately Week 57

  2. PK: Maximum Concentration (Cmax) of LY4298445

    PK: Cmax of LY4298445

    Time frame: Baseline up to Week 52

  3. Pharmacodynamic (PD): Degree of Peripheral B Cell Depletion Following Biopsy in Participants

    PD: Peripheral B cell depletion

    Time frame: Baseline up to Week 52

07

Study locations

2 of 10 sites recruiting
  • Nucleus Network
    Brisbane, 4006, Australia
    Recruiting
    • · Contact+617 3707 2720
    • Gloria Wong · Principal investigator
  • Nucleus Network
    Melbourne, VIC 3004, Australia
    Recruiting
    • · Contact+61 1800 243 733
    • Christina Catherine Chang · Principal investigator
  • Peking University First Hospital
    Beijing, 100034, China
    Not yet recruiting
    • · Contact010-83572211
    • Zhuoli Zhang · Principal investigator
  • Peking University Third Hospital
    Beijing, 100191, China
    Not yet recruiting
    • · Contact010-82266699
    • Rong MU · Principal investigator
  • Xiangya Hospital of Central South University
    Changsha, 410008, China
    Not yet recruiting
    • · Contact0731-89753999
    • Hui LUO · Principal investigator
  • Anhui Provincial Hospital
    Hefei, 230036, China
    Not yet recruiting
    • · Contact0551-62284920
    • Zhu CHEN · Principal investigator
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, 200127, China
    Not yet recruiting
    • · Contact021-58752345
    • Shuang YE · Principal investigator
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325000, China
    Not yet recruiting
    • · Contact0577-55578035
    • Li SUN · Principal investigator
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, 430022, China
    Not yet recruiting
    • · Contact027-85726114
    • Qiubai LI · Principal investigator
  • Clinical Research Hospital Tokyo
    Shinjuku-ku, 160-0004, Japan
    Not yet recruiting
    • · Contact81120023812
    • Hiroyuki Fukase · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 25 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 11, 2025
StartActual
Feb 4, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Japan
Show site
  • Clinical Research Hospital Tokyo · Shinjuku-ku, Japan
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    1 site added — first site in Japan
    Show site
    • Clinical Research Hospital Tokyo · Shinjuku-ku, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07276958
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Feb 4, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559)
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion